Forums  
 
Registration


Reply
 
Thread Tools Search this Thread Display Modes
  #1  
Old 11-19-2016,
AgnesDesro AgnesDesro is offline
Junior Member
 
Join Date: Nov 2016
Posts: 0
Default Bladder Cancer PIII Data in May 2010=Next DNDN

Urocidin (Bladder cancer) PIII results in May 2010 .Urocidin has BLOCKBUSTER POTENTIAL (1-1,5 Billion Dollar Market Potential )

A very big Opportunity here ..Do your own DD !!
Reply With Quote
  #2  
Old 11-20-2016,
AidanKl AidanKl is offline
Junior Member
 
Join Date: Nov 2016
Location: Armenia
Posts: 0
Send a message via ICQ to AidanKl Send a message via Skype™ to AidanKl
Default

Bioniche Life Science (BNC.TO) or (BNHLF.PK) Canadian Stock !

Market Cap: 92 Mio C$
Cash: 30 Mio C$
Price: 1,06 C$


Upcoming Milestones

2009/2010 Conditional license for E. coli cattle vaccine in the U.S.

2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM
Reply With Quote
  #3  
Old 11-21-2016,
aigroinudd aigroinudd is offline
Junior Member
 
Join Date: Nov 2016
Posts: 0
Default

ON vaccine manufacturing centre operational
Reply With Quote
  #4  
Old 11-23-2016,
ajaxunos ajaxunos is offline
 
Join Date: Jun 2014
Location: Moldova
Posts: 0
Send a message via ICQ to ajaxunos
Default

Up in Pre-market ...Positive PIII Results will push this stock to 5$+ !
Reply With Quote
  #5  
Old 11-23-2016,
aitzjida84 aitzjida84 is offline
 
Join Date: Nov 2014
Posts: 0
Default

Bioniche has three businesses with diversified risk/reward profiles: Animal Health, which is expected to generate around $28 million in sales in fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and Food Safety, with Canadian approval and a conditional license pending in the U.S. of a vaccine for reducing E. coli 0157 in cattle feces, and a pipeline of other vaccines.

Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” even though the first of two planned Phase 3 trials has a moderate level of risk, as the refractory patients enrolled in the trial are a “tougher-to-treat” population than was enrolled in the Phase 2 trial, he says.

Mitigating the risk somewhat is the 20% “complete response” hurdle required for Phase 3. That compares with the company’s Phase 2 results, where patients achieved a 46.4% CR rate at 26 weeks in a population that was mainly relapsed but also included a few patients being treated for the first time.
Reply With Quote
Reply

Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT. The time now is .


Copyright © 2005 Trading365.co.uk. All rights reserved.
Maintained by SiliconicPro